Literature DB >> 15495596

[Epstein-Barr virus presence in Colombian Hodgkin lymphoma cases and its relation to treatment response].

Sandra Quijano1, Carlos Saavedra, Susana Fiorentino, Oscar Orozco, María Mercedes Bravo.   

Abstract

The role of Epstein-Barr virus as etiologic agent in Hodgkin lymphoma (HL) development has been supported by the detection of viral DNA in the Reed-Sternberg cell in a subset of HL, and the high levels of latent membrane protein 1 expression in these tumors. To gain further evidence of this relationship, lymph nodes from 67 patients with HL were analyzed for the presence of Epstein-Barr virus using EBERs in situ hybridization and LMP-1 immunohistochemistry. Virus presence was related to histological subtype, patients' treatment response and tumor infiltrating lymphocytes phenotype. EBERs transcripts were found in 67% of the cases and LMP-1 in the Reed-Sternberg tumor cells at a 56.7% rate. The prevalence, as determined by histological subtype, was 69.81% for nodular sclerosing, 85.71% for mixed cellularity and 40% for lymphocyte-rich. Epstein-Barr virus presence was more frequent in children (84.2%) in comparison with adults (60.4%). Positive patients presented higher failure-free survival rates than Epstein-Barr virus negative patients. CD4 positive infiltrating T cells were present in a higher proportion in relation to CD8 positive T infiltrating cells, the mean percentages for both subsets were higher in Epstein-Barr virus positive cases. A high percentage of Epstein-Barr virus was present in HL with a probable association with treatment response. This suggests an application of Epstein-Barr virus detection to use as a prognosis marker in treatment response for HL cases.

Entities:  

Mesh:

Year:  2004        PMID: 15495596

Source DB:  PubMed          Journal:  Biomedica        ISSN: 0120-4157            Impact factor:   0.935


  3 in total

1.  Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL.

Authors:  Mahdi Nohtani; Katerina Vrzalikova; Maha Ibrahim; Judith E Powell; Éanna Fennell; Susan Morgan; Richard Grundy; Keith McCarthy; Sarah Dewberry; Jan Bouchal; Katerina Bouchalova; Pamela Kearns; Paul G Murray
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

2.  Prognostic significance of EBV latent membrane protein 1 expression in lymphomas: evidence from 15 studies.

Authors:  Yuan Mao; Mei Ping Lu; Hong Lin; Da Wei Zhang; Ying Liu; Qing Dong Li; Zhi Gang Lv; Jia Ren Xu; Ren Jie Chen; Jin Zhu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

Review 3.  Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis.

Authors:  Yu-Pei Chen; Wen-Na Zhang; Lei Chen; Ling-Long Tang; Yan-Ping Mao; Wen-Fei Li; Xu Liu; Guan-Qun Zhou; Ying Sun; Tie-Bang Kang; Mu-Sheng Zeng; Na Liu; Jun Ma
Journal:  Oncotarget       Date:  2015-10-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.